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Abstract This article aims to put Hong Kong on the map of East Asia’s biotech
studies by identifying the major themes of biotech innovation specific to the city-
state’s colonial past and postcolonial present and future. I provide evidence of a
concerted effort led by biologist-entrepreneurs to promote the biotech industry in
postcolonial Hong Kong. Through assessing scientific literature, media represen-
tations, business strategies, and programmatic visions of key scientist-entrepreneurs
in Hong Kong’s biotech enterprise, I highlight how factors such as local history and
geopolitical considerations shape the emerging “Hong Kong’s bioscience dream.”
Using the recent discovery of a new recombinant anticancer drug, pegylated human
recombinant arginase (BCT-100), as a case in point, I explore how biotech research
and applications are marketed and interpreted in relation to Hong Kong’s unique
historical, political, and cultural context, thus making it distinct from other Asian
Tigers. My analysis of the featured recombinant drug reveals a set of uniquely
Hong Kong–centered cultural meanings attributed to biopharmaceutical research
and benefits. This case reflects how genetic engineering and biotech research are
configured and imagined within the context of the postcolonial Hong Kong Special
Administrative Region.
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1 Introduction: Biotech in Hong Kong
In 2012 a sponsored supplement titled “Hong Kong in Focus: Asia’s Research Hub”
(Sanders 2012) appeared in the influential magazine Science. This article, produced by
the Science/AAAS Custom Publishing Office with the support of the Hong Kong
Biotechnology Organization, showcased the multitude of research and investment
opportunities that Hong Kong has to offer in the high-tech industry and particularly
in the biotech arena. It commences with an overview section, with quotations from
Chun-ying Leung, chief executive of the Hong Kong Special Administrative Region
(SAR) government, saying that “biotech is an emerging sector that has been desig-
nated a key industry for development” and that “the Hong Kong Government is
determined to promote biotech as a key industry” (Sanders 2012: 1640). The overview
section also features input fromRegina Ip, widely known amongHongKong residents
as the former secretary for security in Tung Chee-hwa’s administration who stepped
down after her controversial handling of the national security legislation case in 2003.
In many ways the sponsored supplement is public relations prose, and the fact that
it appeared in a respected academic publication reflects the sophisticated marketing
campaign of the city-state to reach out to the global scientific community. Albert Yu,
an academic biologist turned entrepreneur who founded the Hong Kong Biotechno-
logyOrganization, explicitly articulates the agenda of the sponsored supplement: “We
want to show the international community that Hong Kong is fully committed to
building and growing this [biotech] industry and that our government, academia,
and industry are all taking proactive roles in contributing to biotech” (Sanders
2012: 1641). At the center of this quotation is not a reference to Hong Kong’s tech-
nological capabilities or its research and development (R&D) infrastructure but, more
important, a declaration of the government’s commitment to biotech. In other words,
what Yu wanted to emphasize, and what this sponsored supplement wanted to com-
municate to the international audience, is the city-state’s unreserved support and
strategic interests in biotech.
The declaration of Hong Kong’s commitment to supporting biotech taps into a
knowledge gap in the STS literature on biotech and biopolitics in East Asia. Informed
readers familiar with Asia’s biotech would notice the absence of Hong Kong among
the leading players of biotech innovation and development in the region. Compared
with the other three Asian Tigers (Singapore, South Korea, and Taiwan), Hong Kong
is the only advanced economy in East Asia that has not been associated with the
pinnacle of biotech modernity: South Korea is renowned for its stem cell research
and clinical R&D facilities, Taiwan has a substantial number of small and medium-
sized enterprises focusing on mid- and downstream biotech marketing and sales
services, and Singapore spent years building its life science megaproject known as
Biopolis. These efforts, coordinated by the developing states in East Asia, attract
scholarly interests in the social, anthropological, historical, and ethical dimensions
of East Asia’s biotech infrastructure. Jennifer Liu (2012) examines the connection
between stem cell research and identity politics in Taiwan; Charis Thompson (2010)
gives a fascinating comparative ethnography of stem cell laboratories in Singapore
and South Korea; Aihwa Ong (2010) probes into the ethics of blood banking in
Singapore; Catherine Waldby (2009) writes about Singapore’s Biopolis, while Axel
Gelfert (2013) analyzes the pre-Biopolis media and policy discourses; and Joseph
2 C. Y. L. Luk
Wong (2011) critically compares the divergent policy and governance issues of bio-
tech in South Korea, Singapore, and Taiwan.
Meanwhile, Hong Kong has received very little scholarly attention. For example,
Wong’s above-mentioned 2011 study noticeably excludes Hong Kong from its analy-
sis of challenges to biotech governance for the three Asian Tigers. The edited volume
Asian Biotech (Ong and Chen 2010) comprises an impressive list of essays exploring
bioethical issues in Asian countries such as India, China, South Korea, Singapore,
Taiwan, Japan, and Thailand, with nomention of HongKong. This, however, does not
mean that one cannot locate literature pertaining to the bioindustry and bioeconomy in
Hong Kong. But most of the existing writings tend to subjugate biotech under the
broader category of R&D policy making (Berger and Lester 1997), innovation and
technology management (Fuller 2010), and innovation system analysis (Baark and
Sharif 2006; Sharif 2010). The few articles that offer an exclusive focus on biotech
(Baark 2005; Wong 2010) generally identify a lack of government commitment to
biotech development in the previous decades.
In light of this literature gap, this article attempts to contribute to the growing body
of literature on Asian biotech by providing a focused discussion on the emerging
biotech discourse in Hong Kong. I argue that the recent biotech initiative in Hong
Kong is well worth examining since Hong Kong is an understudied affluent state in
East Asia that is leveraging its relationship with the world’s second largest economy.
The article proceeds as follows: Section 2 reviews literature that highlights the
dearth of scholarly interests in Hong Kong’s biotech. To seek insights into Hong
Kong’s late entry to the biotech game among the developing East Asian states, I
draw upon relevant literature to give evidence that a shift from the paradigm of
laissez-faire is gradually taking place in postcolonial Hong Kong. Section 3 visits
the previous biotech program in the late colonial decades under the leadership of the
Hong Kong Institute of Biotechnology (HKIB) and the Biotechnology Research Insti-
tute (BRI), to bring out the differences of the postcolonial biotech initiative. Section 4
gives an in-depth analysis of the making of the anticancer drug pegylated human
recombinant arginase (BCT-100)1 by exploring the three means that three Hong
Kong biologist-entrepreneurs and media workers utilized to cultivate public enthusi-
asm for the new drug. I argue that the Hong Kong mainstream newspapers and maga-
zines put the drug on a pedestal by exploiting the identity politics of the Hong Kong
populace. I suggest that the key to understanding the media campaign and the public
expectation of the drug is the relationship between techniques of life sciences and
political discourses. Section 5 compares and contrasts the colonial biotech initiative
1 Pegylated denotes the covalent attachment of the polymer (polyethylene glycol, or PEG) to themolecular
surface of arginase, an enzyme that metabolizes arginine, an amino acid necessary for the survival of both
normal and tumor cells. Since arginine is produced by normal but not tumor cells (especially but not
exclusively hepatoma), the drug essentially depletes intracellular arginine to inhibit the proliferation of
hepatocellular carcinoma (liver cancer cells). The registered name of the drug, BCT-100, derives from the
first three initials of the name of the biotech company, Bio-Cancer Treatment International Ltd., cofounded
by the three Hong Kong scientists who codiscovered this drug. The National Cancer Institute Drug Dic-
tionary names it “pegylated recombinant human arginase I BCT-100” (code name PEG-BCT-100; www
.cancer.gov/drugdictionary?cdrid¼657226, accessed 10March 2016). This article uses the name BCT-100
because it is the term used regularly in clinical trials (NIH 2009, 2010), media reports (Sanders 2012), and
scientific literature (Mussai et al. 2015) by the three Hong Kong scientists who codiscovered the drug
(UGC 2007a; Capital Weekly 2013).
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centered on the antimalaria vaccine TBV25H with the postcolonial wave of biotech
revolution that rests upon the new anticancer drug BCT-100, in order to critically
evaluate the claims of biomedical benefits and innovativeness surrounding BCT-100
vis-a`-vis that of TBV25H, aHongKong–manufactured therapeutic vaccine developed
in the premillennium decades.2 Section 5 also discusses how other biologist-entre-
preneurs leveraged the Chinesemarket force by turning scandalous health problems in
China into profitable business opportunities in Hong Kong. Section 6 discusses the
significance of the research findings within the framework of “communities of fate”
outlined by Ong (2010). I summarize the moral economy of “HongKong’s bioscience
dream”3 by relating its core themes to the three forms of biopolitical communalism
articulated in Ong’s framework. By exploring ways in which life science innovation
shaped the collective fates of the city’s populations, I seek a better understanding of
the ways in which biologist-entrepreneurs help life science applications take root in
postcolonial Hong Kong.
2 Biotech in Hong Kong: A Latecomer among the Late-Developing
East Asian States
The dearth of literature featuring Hong Kong’s biotech reflects a scholarly view
regarding the policy and infrastructure of science and technology in Hong Kong.
Comparing the biotech industrial policies of Hong Kong and Singapore, Lai Si
Tsui-Auch asserts, “The biotechnology industry ofHongKong remains at the ‘infancy
stage,’ whereas that of Singapore has achieved significant milestones in obtaining
patents and commercializing products” (2000: 4). Echoing Tsui-Auch’s analysis,
Gelfert adds: “Whereas the Hong Kong government made no plan and program for
biotechnology—partly because pre-1997 governments had little incentive to develop
long-term high-tech capabilities, given the foreseeable takeover of Hong Kong by
China—the Singapore government set up science parks to foster frequent exchanges
and linkages between industry, academia, and government” (2013: 105). Although
both Tsui-Auch and Gelfert are based in Singapore, their perspectives are generally in
line with the viewpoints supplied by Hong Kong–based scholars. Assessing the weak
biotech industry in post-1997 Hong Kong, Erik Baark described Hong Kong as “the
‘odd-one-out’ among the successful Asian newly industrialized economies” in light of
its meager public R&D expenditure compared with other advanced economies in East
Asia (2005: 10). Moreover, Baark gives a stern assessment of the Hong Kong govern-
2 TBV25H stands for “transmission-blocking vaccine based on the protein Pfs 25 with a histidine tag.”
Transmission-blocking vaccine refers to the vaccine interrupting the development of drug-resistant malaria
parasites in the bloodstream, which acts to “block” the “transmission” of parasites from one individual to
another. Pfs 25 and histidine tags are procedures to improve the quality of the previous generation of
transmission-blocking vaccines, which suffered from the problem of protein degradation. Pfs (Plasmodium
falciparum) 25 is a 25-kDa cysteine-rich protein, a type of recombinant protein with N-terminus degra-
dation, while histidine tag refers to the technique of histidine-tagged nickel-binding purification, which is
used to increase the protein-binding capacity of aminopeptidase. The immunogenicity (immunity-generat-
ing ability) of TBV25H is experimentally shown to supersede that of TBV5 by a substantial degree (Kaslow
and Shiloach 1994).
3 “Hong Kong’s bioscience dream” (香港生科夢) is the caption of a local media report featuring Albert
Yu and his team (Capital 2002).
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ment’s systematic lack of commitment to building the necessary infrastructure to
support biotech: “With reference to systemic failures, the Hong Kong commitments
have been weak both in terms of financial resources and in terms of the creation of
infrastructure. Hong Kong biotechnology continues to suffer from the small share
of support from public as well as private sources” (14). His analysis of a series of
biotech initiatives put forth by the Hong Kong colonial government in the 1990s is
further assessed in section 3 of this article. These examples support the contention
that scholars from both Singapore and Hong Kong basically agree that Hong Kong
had no serious biotech policy or infrastructure in place from the pre-1997 colonial
period to the post-1997 special administrative period. It is this dim view of Hong
Kong’s science and technology affairs that contributes to the knowledge gap in the
STS literature.
One of the common reasons given for the Hong Kong government’s reluctance to
support biotech is its doctrine of laissez-faire, or “positive noninterventionism,”where
the government recedes to a minimalist style of governance while giving market
forces the latitude to take control of industrial policy making. The laissez-faire policy
rationale is underscored by Baark (2005) in his attempt to explain why the HongKong
government did not take any significant action in the 1990s. Likewise, Tsui-Auch
describes the Hong Kong’s industrial policy practice as “functional” where “the state
confines itself to stimulating an ideal market by fulfilling general economic functions”
(2000: 2). Therefore, both Baark and Tsui-Auch seem to attribute the cause of Hong
Kong’s lackadaisical undertaking in biotech to a policy void. The Hong Kong gov-
ernment is hamstrung by a lack of policy justification for public spending, let alone
supporting new technologies such as biotech.
However, more recent studies have begun to explore the limits of the laissez-faire
model (Fuller 2010) and the changing policies and practices in posthandover Hong
Kong. Examining the innovation strategy of the Innovation and Technology Com-
mission (ITC) introduced by the Hong Kong SAR government in 2004, Naubahar
Sharif contends that ITC’s new strategy “represents a significant departure from the
Government’s traditional laissez-faire operating principle of ‘positive noninterven-
tion’” (2010: 418). A paradigm shift in public administration is also identified by
Wong, who suggested that “reducing risk and uncertainty to incentivize otherwise
risk-averse firms to enter into the biotechnology sector is considered excessive gov-
ernment intervention. However, things have begun to change, albeit slowly” (2010:
235). Wong cited the construction of the Hong Kong Science and Technology Park
(HKSTP) in 2001 and its biotechnology initiative introduced in 2004 as supporting
evidence. Phase 3 of HKSTP was completed in 2014, with biotech companies serving
as one of the major focused clusters (HKSTP 2014, accessed in 2016). Wong inter-
preted the construction of HKSTP as an institutional effort to broaden Hong Kong’s
R&D base in the life sciences. Although skepticism lingers around Hong Kong’s
technological capacity to fuel biotech development, Wong suggested that “more
recent developments during the 2000s laid the foundation for considerably more
lofty ambitions over the longer term, which is to turn Hong Kong into a biotech
innovator” (2010: 233).
The prima facie impression of Hong Kong as a merchant’s paradise bereft of any
serious public commitment to the advancement of science and technology is slowly
giving way to the newly constructed image of Hong Kong as a regional biotech
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innovator. Change is afoot in the organization of Hong Kong’s R&D structure and
innovation system that counteracts the prevailing “noninterventionist” conventional
wisdom. Recent developments in Hong Kong reveal a nascent process of strategic
state involvement in driving biotech development. For example, between 2004 and
2006, the term biotechwas used in an ambiguous and all-encompassingmanner by the
ITC.4 However, things began to change after 2010, when the Hong Kong government
unveiled its developmental plan, which featured an increased public funding for R&D,
of which a significant portion is directed to the biotech sector. It is fair to describe
Hong Kong, with its combined quantitative improvement in funding and qualitative
paradigm shift in science policy, as a latecomer to the biotech arena or, to borrow
Wong’s description, “a late entrant into the life sciences sector” (2010: 223).
Perhaps partly because “Hong Kong is a laggard in technological innovation”
(Wong 2010: 223), skepticism abounds with regard to the city-state’s governing capa-
bility or material sufficiency to sustain biotech, which is a cash-burning, high-risk
enterprise. Social critics tend to hail Singapore’s success in this area to satirize Hong
Kong’s underachievement: “Even Singapore has shot ahead with its fledging life
sciences, medical equipment and biotech industries. . . .Hong Kong may fantasize
about going hi-tech. But it is doing a pitiful job compared with our competing cities”
(Lo 2015). Considering the persistent pessimism surrounding Hong Kong’s biotech
development, I evaluate Hong Kong’s recent foray against the backdrop of the pre-
vious biotech endeavor in the colonial period. Essentially, I emphasize the differences
between the postcolonial biotechmomentumwith the previous biotech initiative of the
1990s in order to assess the degree of gravitas of the latest wave of postcolonial biotech
movement.
3 Leveraging Biotech in Hong Kong: Then and Now
Hong Kong government’s first official biotech policy making dates back to 1988,
when the HKIB was established near the Chinese University of Hong Kong, while
the BRI was founded at the Hong Kong University of Science and Technology
(HKUST). In documenting HKIB’s early history and policies to promote downstream
processing and incubation services for biotech firms, Baark (2005) identifies a number
of reasons behind the doom and gloom of HKIB. Baark assigns market, systemic, and
learning failures as the underlying causes for the industrial failure of HKIB’s biotech
policies. First, HKIB did a lousy job in attracting private capital to invest in value-
added biotech operations and failed to create a private biotech market. Second, HKIB
did not do enough to help the local pharmaceutical industry commercialize new bio-
technological knowledge, constituting what Baark called a “systemic failure.” Third,
4 The ITC defines “biotechnology-related companies” as comprising “mainly healthcare-related compa-
nies with business in pharmaceuticals, medicinal or healthcare products of traditional Chinese medicine
origin, and medical devices and diagnostics.” According toWong 2011, several East Asian states purposely
adopt a rather expansive definition of biotechnology, such as the one espoused by the ITC, to include
products and services that are not normally considered biotech to bolster a more optimistic prognosis of
the biotech industry.
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Baark deplores the lack of reflection from the Hong Kong government to learn from
these policy mistakes.
Another fiasco was the university-based BRI, under the administration of HKUST.
Together with the Biotechnology Committee, a science advisory committee set up in
1992, BRIwas intended to liaise academic researchwith policymakers and bioventure
capitalists. Commenting on BRI’s subpar performance, Nancy Ip, BRI’s director and
chair professor at HKUST’sDivision of Life Science, lamented the shortage of private
investment in cutting-edge biotech research. BRI’s business development manager
further ascribed the absence of biotech market to an industrial inertia: “There’s no
industry to pick up technology and run with it” (Nature 2001: 4). As for the discre-
tionary power of the Biotechnology Committee, it was suggested that the committee
exercised no independent control over its financial resources and held no governing
authority (Yuan and Hsu 1995).
The biotech endeavors mediated by the HKIB and the BRI are representative of the
first wave of Hong Kong’s biotech initiative. This phase of biotech development in
Hong Kong was characterized by a noncommittal colonial government, apathetic
venture capitalists, and a dormant research community. As Baark notes, “The research
and innovation culture and atmosphere in the late 1980s and early 1990s was very
weak” (2005: 17). Indeed, investors were reluctant to bet their money onHongKong’s
biotech in the 1990s partly because they did not foresee the emergence of upstream
biotech R&D meeting the needs of downstream biotech demands. The innovation
culture of Hong Kong was weak, and the Hong Kong general public was either
uninformed of or uninterested in biotech products or services. Therefore, a locally
demand-driven biotech market was not anticipated to emerge in colonial Hong Kong.
Compared with the sluggish biotech development in the 1990s, the postcolonial
biotech movement was characterized not only by a much larger scale of government
sponsorship but also, more importantly, by the high-profile capital investment and
research endeavor of entrepreneurial biologists. These scientist-entrepreneurs of
biotechnology were the key architects of “Hong Kong’s bioscience dream” (Capital
2002) by feeding public expectations toward the therapeutic promises of genetically
engineered drugs of local significance and thus creating a niche market that would pay
for these Hong Kong–developed drugs that target regional customers. The next sec-
tion deconstructs the recent discourse surrounding the anticancer recombinant drug
known as BCT-100.
4 The Making of BCT-100: The Rise to Stardom of a Recombinant Drug
In his fascinating study of the history of the biotech enterprise in the United States,
Nicolas Rasmussen put the role of academic biologists-turned-entrepreneurs at the
center of his analysis. As Rasmussen wrote, “The biotech enterprise was one produced
largely by biologists” (2014: 3), even though these biologist-entrepreneurswerework-
ing closely with actors from funding agencies, research institutes, and law firms.
Moreover, Rasmussen suggested that the role of academic biologists was particularly
prominent in developing new drugs because “pharmaceuticals were always the
economic driver of the biotech sector” (1). His excellent biography of five of the
first-generation recombinant DNA drugs—human insulin, human growth hormone,
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alpha interferon, erythropoietin, and tissue plasminogen activator—provides a good
rationale for my drug-oriented analysis in this section.
In and out of the United States, commercial drug development through genetic
engineering has been the most common and the easiest way for academic biologists
to reap profits from the new techniques of molecular cloning. Recombinant DNA
techniques, in particular, allow business-minded geneticists (nicknamed “gene jock-
eys,” as the title of Rasmussen’s book indicates) to tap into the medical marketplace.
While Rasmussen used the drug development stories to assess the influence of com-
merce on the aims, methods, and contents of molecular biology, other scholars have
studied the evolving relationship between university life scientists and the business
world (Pisano 2006), issues of patentability of biotech products (Ducor 1998), the
ethics of pharmaceutical clinical trials (Fisher 2009), and philosophical interpretations
of engineered embryos (Maienschein 2014). These scholarly works offer the meth-
odological grounds to study the politics of the new drug and its ramifications on
biotech development.
Recent breakthroughs in Hong Kong’s biopharmaceutical research are at the heart
of the latest biotechmomentum. The discovery of the anticancer drugBCT-100, led by
a clinical oncologist and two academic biologists, is central not only to the biotech
bandwagon but also to the identity of the HongKong biomedical research community.
The drugwas lauded as the first “homegrown” drug to ever receive investigational new
drug (IND) approval from the US Food and Drug Administration (FDA) to proceed
with clinical trials.5 In recognition of the unprecedented clinical breakthrough, a gold
medal with the jury’s commendationwas awarded to the three HongKong scientists at
the Thirty-Third International Exhibition of Inventions, New Techniques, and Pro-
ducts at Geneva. Even more striking, the birth of the drug was celebrated as “the pride
of Hong Kong people” (Capital Weekly 2013), and the therapeutic value of arginine
depletion (the mechanism on which BCT-100 is based) is heralded as the solution for
other types of “Cantonese cancer” (UGC 2007b). The FDA recognition, the Geneva
honor, and the ethnic connotation are the three means by which Hong Kong biologist-
entrepreneurs groomed the new recombinant drug for stardom.
The story of BCT-100 as told through themedia lens is a hero’s tale. At the center of
the narrative are the three scientists responsible for researching the new recombinant
drug: PaulNing-ManCheng,6 ThomasYun-ChungLeung, andThomasWai-HungLo.
Cheng owns a private clinic in Central, Hong Kong; Leung and Lo are academic
biologists based at the Department of Applied Biology and Chemical Technology at
the Hong Kong Polytechnic University (PolyU). According to Leung and Lo, Cheng
was the first one who came up with the research idea. During Cheng’s professional
interaction with a patient diagnosed with advanced hepatocellular carcinoma (HCC)
in 2001, he noticed that the patient’s periodic health improvement probably had
5 Investigational new drug (IND) applications exempt drugs from many FDA regulations so that they can
be transported or distributed across state lines. The US Code of Federal Regulations (21 CFR part 312)
addresses the procedures and requirements for filing an IND application (“Code of Federal Regulations—
Title 21—Food and Drugs,” www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases
/ucm135680.htm, accessed 10 March 2016).
6 Paul Cheng iswell known inHongKong for treating cancers and tumor-related illness for local celebrities,
such as AnitaMui, who passed away in 2003, and more recently the lawyer-socialite Kai-Pong Chau. A local
tabloid magazine lauded Dr. Cheng as a “divine hand for treating cancer” (治癌聖手; Eastweek 2009).
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something to do with his very low blood level of arginine. Cheng then teamed up with
PolyU-based Leung and Lo to further study the causal relationship between lowering
of blood arginine concentrations and inhibiting cellular proliferation of HCC (UGC
2007a). It took the three scientists nearly six years to produce a significant research
paper on this topic. Their first peer-reviewed article was published in 2007 in the high-
impact journal Cancer Research, published by the American Association for Cancer
Research (Cheng et al. 2007). With this essential publication in hand, they applied
for FDA clearance to conduct clinical trials in 2008 (NIH 2009). Phases I and IIa of
BCT-100 were completed in 2012, with additional stages of phase II still under way.
Jill Fisher (2009) has remarked on the duration and developmental phases of clini-
cal trials. As Fisher details, the clinical development cycle of INDs proceeds in three
primary phases and one secondary phase. After a preclinical toxicity test on animal
subjects, the IND will go through a phase I safety test, which usually enrolls about
28–80 healthy human subjects to go through twenty-one trials, which takes up to one
year to complete. About 70 percent of INDs will proceed to phase II studies, which
normally recruit one hundred to three hundred diseased human subjects. An average
phase II studywill take up to two years and goes through six trials to obtain preliminary
information on the efficacy, tolerability, and other safety information of the drug from
several hundred of patients with the targeted disease. Only half of the INDs will pass
this stage and enter phase III, which is the most commonly known phase in popular
understandings of clinical trials. This phase requires one thousand to three thousand
volunteers diagnosed with the targeted disease to participate in an average of ten trials
to compare the drug’s efficacy against standard treatment or placebo effect over two to
four years. The end of phase III marks the completion of the primary phases of clinical
development cycle, after which the FDA will determine whether a new drug appli-
cation (NDA) will be issued. A secondary phase, phase IV, known as “postmarketing”
research, is in place after the drug appears on pharmacy shelves. Phase IV usually
takes 2–10 years, with the input of several thousand diseased human subjects. The
purpose of phase IV trial is to measure the cost-benefits and short- and long-term
efficacy of the drug. Only 25–30 percent of INDs will survive the entire clinical
development cycle and become established medical treatments (Fisher 2009).
Because the clinical trials of BCT-100 are still ongoing,7 it is difficult to tell when
or whether it will get to the next step—filing an NDA.8 Cheng, the leading oncologist
on the team, certainly realized the risks and challenges ahead. In a Chinese-language
magazine article intended for local audiences, Cheng relates the hardship that he and
his team had endured throughout the R&D stage of BCT-100. Cheng and the com-
pany’s cofounder Jun Sing Lee told the reporter, “[We] wouldn’t have embarked on
this process had we known how difficult it was going to be.” They emphasize that it
was all the more arduous for their team because “the United States has no confidence
in Hong Kong’s biopharmaceutical research” (Capital Weekly 2013). The total time
7 Phase III trials of BCT-100 are still recruiting participants at the time ofwriting; see clinicaltrials.gov/ct2
/results?term¼BCT-100&Search¼Search (accessed 7 March 2016).
8 The NDA (new drug application) is defined as “the vehicle through which drug sponsors formally
propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.” (www.fda.gov
/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/New
DrugApplicationNDA/, accessed 10 March 2016).
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spent on conducting laboratory experiments for theHongKongR&D team, inCheng’s
estimation, was three to five times more than their Euro-American counterparts in
order to gain the coveted IND clearance. Despite these difficulties, Cheng says, “When
our achievement is recognized by the US biopharmaceutical authority, I feel that all
the wait and tribulation are worthwhile” (Capital Weekly 2013). The weight of the
FDA recognition of BCT-100 should not be underestimated. As Cheng explains its
significance on the company’s home page, “It is challenging to conduct bio-techno-
logical research in Hong Kong. The issuance of US FDA’s IND to conduct clinical
studies in the US is a stamp of approval that our technology is on a par with the rest of
the developed world” (BCT Company News 2012). Echoing Cheng’s characteri-
zation, Lee said that the primary motivation behind the making of BCT-100 is to
improve the overall biopharmaceutical R&D capacity of Hong Kong, with profitabil-
ity only a secondary concern (Capital Weekly 2013). These biologist-entrepreneurs’
public-good-seeking impetus is further highlighted by local media. Sing Tao Daily
(2012), HongKong’s second largest Chinese-language newspaper, communicated the
importance of theUS accreditation of BCT-100 by describing the drug as “HongKong
manufactured” (港產), rather than using the generic label “China-manufactured”
(國產). In the body text, the drug was upheld as “Hong Kong’s first independently
researched and developed new drug for curing advanced liver cancer” (香港首隻自主
研發的晚期肝癌新藥, my emphasis).
While it is an overanalysis to make too much out of one media portrayal, it seems
appropriate to view the media discourse surrounding BCT-100 through the prism of
what Sheila Jasanoff called the “alliance between biology and power.” In contem-
plating the relationship between biotechnology and imperialism, Jasanoff put forth the
idea that biotech and life science technologies in general have served as instruments
for exercising biopower of the governing elites since the imperial age: “The life
sciences, as much research has shown, have long been implicated in serving the
designs of empire builders. Modern biotechnology, I suggest, can similarly be
drawn into the service of possible imperial constructions, and I ask in what ways
this particular global production system is likely to influence today’s transboundary
exercises of political, economic, and cultural power” (2006: 276). Jasanoff is of the
view that biotech is a means that the corporatized neoliberal state used to justify and
maintain its governing legitimacy. From this perspective, the discovery of the new
drug captures the attention of the Hong Kong media because it resonates with the
populist imagination of the local community: it relates to “the biopolitical imagination
of the neoliberal state and its corporate partners, whose innovative capacity is as
essential to underwriting state action as is the capacity of expert professionals to define
and apply the technical criteria of governmentality” (283). While the media depiction
of BCT-100 highlights the newcomer status ofHongKong in the global biotech sector,
it is not separate from the global politics of biotech.
The recent biotech boom inHongKong offers a case in point to analyze the past and
present connection between biological knowledge and power consideration. A sketch
of the sociopolitical history of Hong Kong is perhaps apropos: Hong Kong is not
a nation-state, an independent country, or a legitimate member in the United Nations.
Its complicated history as a former British colony and the first example of China’s
implementation of “one country, two systems” (a notion invented by Deng Xiaoping
to integrate Taiwan, eventually, into China’s sovereignty) sets it apart from the rest of
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Asian Tigers.9 From a crown colony in the British Empire to a special administrative
region under the People’s Republic of China, Hong Kong also transformed from being
“the world’s greatest experiment in laissez-faire capitalism,” as Milton Friedman
dubbed it (Economist 2010), to the first series of experiments in implementing
capitalist systems in a titular communist country. In examining the history of the
Bacteriological Institute of Hong Kong, Theresa MacPhail wrote that it “is particular
only to Hong Kong, imbued with the city’s colonial past as an important trade hub and
center of British colonial rule” (2014: 86–87). MacPhail further suggested that it is
felicitous to view Hong Kong’s infectious disease research and public health policy
making via “the dual lenses of its postcoloniality and its ‘Chineseness’” (78) because
the city-state has never been able to completely shake off either the haunt of
the colonial past or the apprehension of China’s future. I concur with MacPhail’s
characterization of Hong Kong, and would like to add that this type of postcolonial
negotiation is by no means limited to the city’s epidemiological research; rather,
the city’s latest biotech discourse on BCT-100 cannot be understood without this
conceptualization.
With this context in mind, it is perhaps understandable why entrepreneurial biol-
ogists such as Cheng are eager to highlight Hong Kong’s biopharmaceutical R&D
capacity (which was absent in colonial Hong Kong), while the journalists at Sing Tao
Daily emphasized the locality of the genesis of BCT-100. Both scientific and media
actors were probing into the identity crisis of the Hong Kong people. Trapped in the
mode of what MacPhail called “postcolonial temporality,” the average Hong Kong
psyche is afflictedwith an enduring identity crisis, which again is unique among fellow
East Asians: South Koreans are fanned by a fervent nationalistic sentiment toward
Hwang Woo-suk’s stem cell research (Thompson 2010); Taiwanese are highly con-
scious of the military-political ramifications of sitting in the shadow of a rising China
(Liu 2012); Singaporeans celebrate their half century of independent statehood while
being acutely aware of their resource shortage as a tiny state (Gelfert 2013). Even
though both Hong Kong and Singapore fall under the “technoglobalist” innovation
category (Keller and Samuels 2003), this technoglobalist impulse is differently arti-
culated inHongKong. Specific toHongKong is the opportunity and challenge offered
by its geopolitical proximity to China. Pro-China business leaders tend to emphasize
the lucrative opportunity that closeness provides: “We really are at the doorstep of the
hugeChinesemarket. That is something that other competitors cannot challenge. They
can’t move their countries closer to China!” (Sanders 2012: 1646). But proximity can
also breed contempt. The perennial identity crisis of Hong Kong people is symp-
tomatic of the psychosocial burden of living in China’s immediate vicinity, which
sets Hong Kong apart from other East Asian sites of inquiry.
While the Sing Tao Daily reporters displayed pride in the FDA approval of BCT-
100, previous awards set a powerful stage for the scientist’s claim of the medical
benefits of the homegrown drug. Prior to the FDA recognition, the goldmedal awarded
by the Geneva international convention was another important way to affirm the
collective identity of Hong Kong’s biomedical researchers, for whom a stamp of
9 Taiwan shares a substantial Japanese colonial history with South Korea. Singapore was once a British
crown colony, but it declared independence in 1965, whereas Hong Kong never achieved political
independence.
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approval from the international community is highly valued. The popular tabloid
newspaper Apple Daily (2005) report of the drug’s gold medal highlights the endeav-
ors spearheaded by academic scientists Leung and Lo at PolyU. The title of the report,
“PolyUSucceeds in the R&Dof anAnti-Liver Cancer Drug,” puts the local university,
rather than the biologist-entrepreneurs, in the spotlight. Subsequent to theApple Daily
coverage, the Research Grants Council featured the discovery of BCT-100 in its
biannual newsletter, Research Frontiers, under the aegis of the University Grants
Committee (UGC).10 Titled “New Cancer Drug Breakthrough for Hong Kong,” the
article put the exclusive focus on Leung and Lo, with a picture of the two academic
scientists in the main text and their contact information at the end of the article (UGC
2007a). Cheng was not particularly featured in this UGC-sponsored article probably
because he was a private practitioner rather than an academic scientist working in an
UGC-funded institution. The central figure in the article is Leung, who summarized
the significance of BCT-100 this way: “The breakthrough also won us a Gold, as well
as a Special Gold Award from theMinistry of Education and Research of Romania, at
the 33rd International Exhibition of Inventions, New Techniques and Products at
Geneva and has generated strong interest from around the world. Most important,
however, is the ray of hope it will bring to liver cancer patients and possibly to other
cancer patients as well” (UGC 2007a). TheGeneva accolade was regarded as unprece-
dented glory to the Hong Kong biomedical research community before the advent of
the FDA approval. The Beijing-backed newspaper Global Times (2005) also reports
on the Geneva prize with an article focusing on the international honor. Unlike the
Hong Kong–focused discourses in Sing Tao Daily and Capital Weekly, the Global
Times’s depiction of the drug as “Hong Kong’s New Drug” is ambiguous because it
does not differentiate the difference between Hong Kong–manufactured and China-
manufactured products, nor does it highlight the specificity of Hong Kong’s R&D
capacity. In the text, BCT-100 is described as “the first drug researched and developed
in Hong Kong to go through clinical trials” (首項在香港研發並可進行臨床試驗的
藥物). This description indicates that Hong Kong was merely a locale, the birthplace
of BCT-100, but it is not clear whether Hong Kong researchers or mainland Chinese
students studying in Hong Kong universities were responsible for the BCT-100 R&D
activities.11 Given a lack of distinction between Hong Kong and China and a lack of
attribution to Hong Kong–specific cultural rhetoric, it seems that the way the Global
Times foregrounds the international recognition of the drug reflects the strategic inter-
ests of this People’s Daily–sponsored newspaper.
The final recipe to cultivate public enthusiasm toward themedical benefits of BCT-
100 is the invocation of “Cantonese cancer.” In the same issue of Research Frontiers
that publicized the discovery of BCT-100, an article by the title of “Gene Mapping
10 The UGC was established in Hong Kong in 1965 to administer public funding to higher education
institutions. A few years later, the government set up a Research Grants Council under the umbrella of
the UGC to advise and monitor the use of public research grants in these academic institutions. UGC and
RGC are the primary funding vehicles for the higher education sector in Hong Kong, where nearly all of the
higher education institutions are publicly funded. For more information, see www.ugc.edu.hk/eng/rgc
/index.htm (accessed 10 March 2016).
11 Most laboratory-based postgraduate science students in Hong Kong come from mainland China,
which causes distress among the disgruntled younger generation who blame their Chinese compatriots
for “stealing” education opportunities from them.
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Fights ‘Cantonese’ Cancer” discussed the research outcomes of molecular geneticist
Lo Kwok-Wai from the Chinese University of Hong Kong. Wai’s research agenda
focused on the genome mapping of pharmacological oncogenes for nasopharyngeal
carcinoma (NPC), a type of head and neck cancer. The article commenced with a brief
introduction of NPC as a Cantonese-prone cancer: “NPC, a relatively rare type of head
and neck cancer, is also known as the ‘Cantonese’ cancer in view of its high prevalence
among the Southern Chinese and those of Cantonese origin. Around 80 percent of the
illness occurs in southern China and among Chinese in the Southeast Asian region”
(UGC 2007b). Although the discursive image of “Cantonese cancer” was specifically
applied to NPC rather than all types of cancers, the rest of the article established the
linkage between gene mapping and cancer therapy in general. The government’s
funding agency took interest in the genetic mapping of NPC cells due to its potential
to enable “the development of anti-cancer drugs and newmethods of treatment” (UGC
2007b). In the same issue of Research Frontiers, Leung remarked on “the ray of hope
[BCT-100] will bring to liver cancer patients and possibly to other cancer patients
as well” (UGC 2007a). The commonality between genetic therapy based on NPC
genomemapping and arginine deprivation therapy derived from BCT-100 is that they
both demonstrate a regional (i.e., Cantonese-speaking region) need and demand for
new forms of cancer treatment. This is evident in the joint attempts to generalize a
specific type of research on a specific type of cancer to other forms of cancer treat-
ments. On the one hand, Wai gave the prognosis of the oncogenetic study of NPC:
“Looking forward, morework is being done in the effective use of these gene therapies
to explore the anti-tumor effects of various pharmacological agents” (UGC 2007b).
On the other hand, Leung and Lo have since broadened the arginine depletion research
agenda from HCC (liver cancer cells) to melanoma (Lam et al. 2010) and prostate
cancer (Hsueh et al. 2012), whereas Cheng was involved in the study of the antileu-
kemia effects of BCT-100 (Mussai et al. 2015). In other words, the label “Cantonese
cancer” is specific to NPC, but the therapeutic value of oncogenetic treatment is not.
In her seminal study of the meteoric rise of proto-oncogene theory in cancer
research, Joan Fujimura suggests “different actors used proto-oncogene research to
maintain and extend their lines of work and simultaneously extended the reach of
proto-oncogene research and molecular genetic technologies” (1996: 152). Although
this paper does not examine the history of oncogene research, Fujimura’s insight is
instructive because what her study underlines is the social construction of cancer
knowledge by scientists and nonscientists. As she argues, “The enthusiasm for a
particular research problem, and for a particular technical approach, is a social phe-
nomenon” (3). Not only is cancer research a social phenomenon, but cancer’s alarming
health threat to the developing world has become a global issue. Margaret Chan,
director general of the World Health Organization and former director of health in
Hong Kong, recently commented on the global health crisis posed by noncommunic-
able disease: “The worldwide increase of non-communicable diseases is a slow-
motion disaster . . . but the unhealthy lifestyles that fuel these diseases are spreading
with a stunning speed and sweep” (Chan 2011).
As China becomes the world’s second largest economy, a staggering number of its
people are now suffering from preventable, noncommunicable diseases, of which
cancer is a leading cause of death (American Cancer Society 2016). Therefore, the
economy of cancer therapy constitutes a seller’s market for oncological treatment, and
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this also explains why cancer commands the highest level of scientific enthusiasm
in biotech and pharmaceutical companies, followed by diabetes and rheumatoid
arthritis. Indeed, the scientific enthusiasm that surrounds BCT-100 was jointly pro-
duced by molecular geneticists, representatives from academic funding agencies
public health officials, and stakeholders from biotech firms. Despite the growing
skepticism among the scientific community regarding the equivalence of NPC and
“Cantonese cancer,”12 academic biologists and funding agencies in Hong Kong show
no sign of deterrence from drawing this connection. The relevance of the cultural
image of Cantonese cancer to the perception of BCT-100 illustrates the interplay
between the medical promise of molecular genetic cancer research and the business
enthusiasm of the drug-centric biotech enterprise.
In many ways, BCT-100 is a paradigm-shaping drug that is on its way to becoming
the first homegrown “blockbuster” drug in Hong Kong. Bombarded with many rosy
portrayals and some overinflated promises, one is prompted to ask how different
BCT-100 really is fromother previousHongKong–developed drugs. The next section
compares and contrasts the case of BCT-100 with the antimalaria vaccine TBV25H,
followed by investigations of other contemporary biotech developments, to highlight
the discontinuity of the postcolonial biotech dynamics.
5 From TBV25H to Focusing on Biomedical Problems of Regional Significance
Although Leung narrated BCT-100 as “the first drug to be developed in Hong Kong to
proceed to clinical trials” (UGC 2007b), other scholars had offered pre-BCT-100
events to contend with this notion of unprecedented biomedical innovativeness. In
analyzing Hong Kong’s “failed” biotech initiative in the 1990s, Baark described the
clinical trial of TBV25H, an HKIB-sponsored vaccine, as “the first human safety trial
of a therapeutic drug developed in Hong Kong” (Baark 2005: 19). As an antimalaria
vaccine built upon the mechanism of blocking the transmission of malaria parasites,
the R&D of TBV25H was undertaken by David Kaslow and Joseph Shiloach from the
Molecular Vaccine Section of the Laboratory of Malaria Research at the National
Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of
Health (NIH). After the preclinical research findings were published in 1994 (Kaslow
and Shiloach 1994), HKIB applied for an R&D partnership grant from the United
Nations Development Program,World Bank, andWorld Health Organization Special
Program for Training in Tropical Disease Research. According to Albert Chang, then
HKIB chairman, the purpose of the R&D partnership grant was “to train research
personnel in HKIB’s Good Manufacturing Practice–Manufacturing Technology
Center . . . to scale up the production” of TBV25H (1999: 2). In other words,
TBV25H was first researched in the United States, and only after the upstream
research was completed was HKIB interested in the mid- to downstream production
of the vaccine for the purpose of staff training. The R&D partnership grant enabled
HKIB to collaborate with the NIAID to file an IND application to conduct the clinical
12 A recent article published in the Chinese Journal of Cancer questioned the appropriateness for calling
nasopharyngeal carcinoma “Cantonese cancer” in view of new genetic and historical analyses (Wee et al.
2010).
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trials of TBV25H in Hong Kong and the United States simultaneously. The role of
HKIB is mainly to “manufacture the bulk clinical trial materials for the Phase I human
studies” (Chang 1999: 2).
Compared with the glory of BCT-100, the clinical development of TBV25H was
lackluster and not very indigenous to Hong Kong. Although both TBV25H and BCT-
100 involved some degrees of input fromHongKong in filing and conducting the FDA
clinical trials, TBV25H was not primarily a Hong Kong–driven biomedical inno-
vation. The high-end research phase of TBV25H was conducted elsewhere, with no
participation from Hong Kong scientists. The contribution of Hong Kong in the clini-
cal development of TBV25H is marginal in the sense that Hong Kong was mainly
involved in the low-end manufacturing phase of clinical trial materials. Moreover,
although both the NIH and HKIB were behind the IND application, the partnership
grant through the special training program allocated to HKIB was used to finance the
application. Couched in the name of international collaboration, the uneven resource
distribution reflects the asymmetrical power dynamics behind the NIH–HKIB
partnership. In the clinical development of TBV25H, HKIB was left in a dependent
position by following the lead of the NIH.
That the clinical development of TBV25H was mainly driven by the NIH rather
than HKIB provides a strong but incomplete explanation for its frigid reception from
the Hong Kong mainstream society. Unlike the expressed media interests over BCT-
100, TBV25H received no popular portrayal from any local media. The only media
avenue that mentions the clinical achievement of TBV25H is HKIB’s own website.13
The paucity of media interest in TBV25H likely has to do with the perceived irrel-
evancy of the antimalaria vaccine due to the changingmedical needs of theHongKong
society. While malaria was once infamously regarded as “Hong Kong fever” among
the British sailors in the 1890s, it had ceased to plague the postwar Hong Kong
population by the 1970s thanks to the antimalaria efforts of the colonial government
(Yip 2009). In writing about the history of malaria control and sanitation programs
in modern East Asia, Ka-che Yip (2009) explicated the Eurocentric image of tropical
disease as part of the “uncivilized” and backward culture of the overseas colonies.
As Yip argued, “The British in Hong Kong also understood many of the diseases that
they encountered, including malaria, to be products of the uncivilized and unwhole-
some lifestyle of the local population and the untamed environment they lived in.
Their civilizing mission was certainly reinforced by their sense of superior Christian
morality” (2009: 5). This quote displays the explicit connection between imperialist
ideology, notion of religious superiority, and efforts of disease control and prevention
in early colonial Hong Kong.
The history of antimalaria policy in Hong Kong reveals a specific mode of colonial
malariology that was firmly entrenched in British imperialism. However, with the
eradication of malaria in the late twentieth century, the fin de sie`cle idea of “tropical”
medicine was becoming more distant and immaterial in the mind-set of average Hong
Kong citizens. Malaria was no longer a major health threat by the 1970s, at the same
time as Hong Kong was transformed into a newly industrialized economy. In 1970 the
13 See Hong Kong Institute of Biotechnology, www.hkib.org.hk/gb/services/biologics.htm (accessed
10 March 2016).
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five leading causes of death in Hong Kong were, in descending order of mortality rate,
cancer, heart and hypertensive diseases, pneumonia, cerebrovascular lesions, and
tuberculosis (Yip 2009). The Hong Kong Department of Health (2007, accessed in
2016) reckoned that in 2006 more than 61 percent of the total mortality rate in Hong
Kong was attributable to preventable noncommunicable diseases, of which cancer
accounted for over 32 percent of registered deaths. Cancer also ranked first and killed
two-fifths of the population prematurely, asmeasured by the number of potential years
of life lost at seventy-five years of age. With the economic development and health
enhancement, “tropical” diseases such as malaria ceased to afflict the Hong Kong
populace, for whom noncommunicable diseases such as cancer presented a much
more immediate health concern. While I do not deny the effect of the legacy of
epidemic control on present public health policy making,14 I do want to highlight
the perceived irrelevancy of malaria research to the general needs of the Hong Kong
people in the twenty-first century. The perceived urgency of biotech research to the
local medical needs is an important factor separating TBV25H from BCT-100. While
TBV25H is seen as serving (chiefly) the affected population in developing tropical
countries, BCT-100 is not. The anticancer drug is much more marketable to the Hong
Kong population than is the antimalaria vaccine. Table 1 summarizes the major points
of differences between TBV25H and BCT-100.
Through the above comparative analysis, I hope to put into perspective the post-
colonial biotech development empowered by Hong Kong biologist-entrepreneurs.
Unlike the previous wave of biotech initiative, as typified by TBV25H, the postcolo-
nial biotech enterprise was shaped by a much more salient and vigorous participation
of business-savvymolecular biologists, and their efforts are not limited to the research
and promotion of BCT-100. In what follows, I examine other entrepreneurial attempts
of academic biologists with the emphasis placed on the business-oriented motive that
underlines the postcolonial biotech development in Hong Kong.
The media-concerted campaign of BCT-100 transforms the three Hong Kong sci-
entists into pioneering inventors and life-saving scientists rather than profit-seeking
entrepreneurs. Yet the very name of the drug, BCT-100, is a reminder of the corporate-
driven nature of biopharmaceutical research.What lies behind the development of the
first homegrown drug is not just the biotech company by the name of Bio-Cancer
Treatment Ltd. but, more important, the growing realization among the academic
biologists that they need to focus on biomedical research topics of regional signifi-
cance if they want to turn novel biomedical technology into commercially viable
products.
In posthandover Hong Kong, academic biologists were among the first groups of
actors to recognize the need to pursue biomedical research topics of regional relevance
in order to catalyze the local biotech development. Michael Yang, department head of
biomedical sciences and chair professor of chemistry and biomedical sciences at the
City University of Hong Kong, spoke of the significance of “focusing on biomedical
problems of regional importance” in order to “find a niche in the crowded” market-
place of biotech innovation (Nature 2001: 4). Yang cofoundedMultigeneDiagnostics,
14 MacPhail (2014) recently examined the linkage between the epidemic past of colonial Hong Kong and
the post-2003 global efforts against new types of communicable diseases triggered by the outbreak of SARS
(severe acute respiratory syndrome).
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Ltd., a City University spinoff biotech firm specializing in molecular diagnostics. As
the first biotech company admitted to the Incu-Bio Business Incubation Program at
HKSTP in 2009, Multigene had the ambitious goal to harness the rapidly growing
Chinesemarket (South ChinaMorning Post 2010). As the executive director ofMulti-
gene told themedia, “We have a number of products that are in great demand in China,
such as the human papillomavirus (HPV) detection and genotyping kits for cervical
cancer screening” (Sanders 2012: 1643). HPV is a type of sexually transmitted disease
(STD) that accounts for 70 percent of cervical cancers worldwide. According to a
CNN news report, STD-related diseases are on the rise in China, which generates
debates over the need to promote sex education in China (Steinfeld 2014). The HPV
vaccine is currently only available in Hong Kong, but Chinese scientists are now
urging the Chinese government to subsidize a semimandatory HPV vaccination pro-
gram for the high-risk community (Zhang et al. 2013). As STDs become a bigger
Table 1 Major characteristics of TBV25H versus BCT-100
Characteristic TBV25H BCT-100
Full name Transmission-blocking vaccine
with Pfs 25 and histidine tag
Bio-cancer treatment-100
(pegylated human recombinant
arginase)
Period of discovery Colonial Hong Kong Postcolonial Hong King
Use Malaria immunization Cancer therapy
Target audience Affected population in
tropical countries
Primarily Hong Kong cancerous
population
R&D site National Institutes of Allergy and
Infectious Diseases at the
National Institutes of Health,
United States
Hong Kong Polytechnic
University, BCT
International Ltd., Hong Kong
Principal investigators David Kaslow, Joseph Shiloach Paul Cheng, Thomas Leung,
Thomas Lo
Clinical collaborators Prince of Wales Hospital, Chinese
University of Hong Kong,
US National Institutes of Health
Queen Mary Hospital,
University of Hong Kong
Chinese University of Hong Kong
Sponsors United Nations Development Program,
World Bank, and World Health
Organization Special Program for
Research and Training in Tropical
Diseases
BCT International Ltd.,
Hong Kong Science and
Technology Park, Hong Kong
Polytechnic University
Portrayal “First human safety trial of a
therapeutic drug developed
in Hong Kong”
“The pride of Hong Kong people”
“Hong Kong’s first independently
researched and developed new
drug for curing advanced
liver cancer”
Biotech in Hong Kong 17
threat to China’s public health, they represent a more lucrative market for Multigene
and other Hong Kong biotech firms making similar products. Multigene’s strategy to
prioritize STD diagnostic services exemplifies Yang’s philosophy of “focusing on
biomedical problems of regional importance.”
The success of Multigene attracts more companies to follow its business model.
Vitargent Biotechnology Ltd. is a Hong Kong start-up firm that concentrates on food
detection technology. The company recently announced a new testing method for
detecting chemical toxins in food and cosmetics by using zebrafish embryos as an
active agent. The innovative food-testing technologywas intended to capitalize on the
food safety problems in China, which became ignominious after reports of babies
dying from consuming melamine-contaminated formula in 2008. Besides poisonous
milk, recycled cooking oil (otherwise known as “sewer oil”), questionable meats, and
fake eggs also triggered alarming concerns over the reliability of China-supplied food
products.15 The food safety issue might be a matter of public embarrassment if not
a legitimacy crisis for the governing elites in Beijing, but it is viewed as a thriving
market in the eyes of Vitargent executives. As a South China Morning Post article
suggests, Vitargent “sees a huge opportunity in China, where multiple food scandals
have rocked consumer confidence, particularly with regard to milk powder and cook-
ing oil” (Griffiths 2015). It is uncertain whether Vitargent will reap profit from its
biotesting technology, although a San Francisco–based venture capital group seems
to think so, as it has invested somewhere between US$5 million and US$15 million in
the Hong Kong company (Griffiths 2015; Ma 2015).
Multigene and Vitargent set the trajectory for pro-business Hong Kong biotech
firms to capitalize on the booming Chinese market. The magnetic market force of
mainland China attracts Hong Kong biologist-entrepreneurs to invest in biotech ser-
vices that dovetail with the growing demands from the Chinese customers. As Wong
acutely captures, “China offers ‘low hanging fruit’ for would-be bio-entrepreneurs
based in Hong Kong” (Wong 2010: 227). HPV vaccine and food testing are just two
examples of these “low hanging fruits” offered by the immense Chinese market.
Through harvesting these fruits in the flourishing Chinese garden, the Hong Kong
biotech firms are actually shaping an emerging regional biotech market. Even though
the motive is profit, these Hong Kong biotech firms still play an important part in
creating a local biotech marketplace, which has been long awaited by investors and
scholars alike. As late as 2004, a book focused on Asia’s biotech industry suggested:
“The major problems with financing biotech ventures in Hong Kong are that there is
only a small local market for biotech products and that the country has a history of
expertise in finance and the service industry, not in world-class research and develop-
ment” (Bergeron and Chan 2004: 257). The recent efforts of Hong Kong biologist-
entrepreneurs seem dedicated to address the issue explicitly raised by Bergeron and
Chan, and a feeble biotech market and a weak R&D capacity are no longer the main
hindrances to Hong Kong’s biotech development. The biomedical breakthrough of
BCT-100 strengthened Hong Kong’s R&D base, while the pro-China business
approach of the Hong Kong biotech firms bolstered a regional biotech market.
Although biotech is an inherently risky and speculative enterprise, these recent
15 See Foster 2011 for an inventory of top ten Chinese food scandals since 2008.
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strategies directed by the entrepreneurial life scientists have significantly changed the
stereotypical image of Hong Kong as a financial paradise unsuitable for biotech
research and market development.
6 Discussion: Hong Kong and “Communities of Fate”
In theorizing the relationship between biotech and bioethics in Asian countries, Ong
(2010) introduced an analytical framework called “communities of fate” to make
sense of new biotech regimes in multiple locations. Grounded in an anthropological
approach to bioethics, the concept of communities of fate highlights the interactions
among politics, science, and ethics in Asian contexts that are distinct frommainstream
Western ethical reasoning. Specifically, three practices are constitutive of such com-
munities of fate. First, the biotech programs in Asia’s emerging economies are mostly
state driven and fueled by a strong sentiment of postcolonial nationalism. Second,
biotech innovations often bring with them hidden symbolic meanings, as imprinted in
the genetic predisposition for certain diseases among Asian populations. Third, tra-
ditional beliefs about ethnicity and folk religion are carried over to interpret new forms
of biomedical knowledge and practices.
The preceding sections in this study of Hong Kong’s biotech reveal both conver-
gence and divergence between the empirical data in Hong Kong and the theoretical
underpinning of communities of fate. The essential features of “Hong Kong’s
bioscience dream” correspond nicely to each of the three components in Ong’s tri-
partite theory. Regarding postcolonial nationalism, Ong writes: “As state-led enter-
prises, biotechnologies are allied to nationalist efforts to overcome past humiliations
and to restore national identity and political ambition. The examples mentioned above
all register a deep nationalist fervor in the race to be ‘number one’ in cutting-edge
sciences, with its promise of a lucrative science-driven economy” (2010: 3). At first
glance, Hong Kong seems to diverge from the modular regime of state and nationalist
collectives in biotech governance. Although many biotech enterprises in Hong Kong
(e.g., Multigene and Vitargent) are private rather than state owned, the postcolonial
biotech boom in the city is heavily backed by the SAR government, as evident in the
reportage of SAR government officials in the 2012 Science-sponsored supplement
that I discussed in section 1 (Sanders 2012). In addition, the marketing campaign of
BCT-100 exhibits a postcolonial desire to enhance local identity and prestige by
presenting the drug as, among other things, the first homegrown experimental drug.
Corresponding to the second component in Ong’s theory, the symbolic dimensions
of Hong Kong’s bioscience dream are illustrated in the advertisement strategies of
BCT-100. In advertising the medical benefits of BCT-100, the three biologist-entre-
preneurs did not just highlight the purely scientific facts of the drug. Rather, Cheng
commented on the unusually high level of skepticism held by the FDA regarding the
city’s R&D capacity; Leung and Lo cited the Geneva accolades to bolster the unpre-
cedented achievement of the drug, even though TBV25H preceded BCT-100 as the
first Hong Kong–manufactured drug to go through human safety clinical trials.
The third aspect of communities of fate relates to the new forms of assemblages
between biotech innovation and traditional belief systems. As my analysis shows, the
emergence of new forms of biotech knowledge in Hong Kong is constructed with the
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cultural and political tropes of independence, ethnic pride, and regional resources.
BCT-100 is “the pride of Hong Kong” because it is the first homegrown drug that
focuses on a common noncommunicable disease that also resonates with the “Can-
tonese” ethnicity, which makes the drug salable to the Cantonese-speaking commu-
nity in southern China. Making the new recombinant drug was not only a biomedical
breakthrough but also a convergence of the life-saving medical promise with the
moneymaking commercial interests of biotech enterprise. Similar to other critical
studies of biotech in East Asia, Hong Kong’s biotech research offered a pivotal
point of reference to understand the multiple layers of meanings that are integrated
into “Hong Kong’s bioscience dream.”
In the meantime, the Hong Kong case also offers points of divergence from East
Asia’s communities of fate. The array of ethnographic studies in Ong and Chen’s
coedited volume Asian Biotech “explores the political and ethical implications of
biotechnologies outside contexts of Western advanced liberalism” (Ong 2010: 43).
Yet HongKong does not fall under this category of non-Western developmental states
that tend to deprioritize liberal democracy. Despite the many quarrels between policy
makers, legislative councilors, and the general public in Hong Kong, few called into
question the full extent ofWestern-style capitalism practiced in Hong Kong. Not only
does the city-state take pride in its total embrace of the free enterprise system, but it is
also willing to tolerate the many social consequences that came with widespread
income inequality. While economic fluctuation and social unrest sometimes invite
civil disobedience, protestors often assign culpability to China’s overlordship of Hong
Kong rather than the systematic weaknesses of radical capitalism. It is safe to say that
many Hong Kongers openly espouse the British legacy of free trade and liberal
democracy, while few question the footprints of Western imperialism and racial dis-
crimination. This political culture is discernible in the biotech sphere, for it is the
business-minded biologists rather than state actors or government officials who are
responsible for creating the momentum that shapes the postcolonial biotech phenom-
enon inHongKong. Inspired by the need to “focus on biomedical problems of regional
importance,” academic biologists from university spinoffs skillfully specialized in
biotech products that were in great demand in China, such as HPV diagnostic kits and
biotesting technology. Realizing the need to find a regional niche market to sustain
new technologies, biologist-entrepreneurs were incentivized to connect the pull of the
Chinese market with the push of locating regional biomedical problems that were
marketable to Chinese customers. While I do not uncritically celebrate the discovery
of BCT-100 or other Hong Kong biotech inventions, what I hope to illustrate is the
salient role of biologist-entrepreneurs in shaping the city’s biotech sector.
This article is among the first in East Asian STS scholarship to map Hong Kong’s
biotech landscape within what Fu Daiwie called the “distinctive East Asian networks”
(Fu 2007). To date, Hong Kong has received sparse scholarly interest in the burgeon-
ing East Asian STS scholarship. The standard view regarding biotech in Hong Kong
holds that the city had no serious biotech commitment under way in either pre- or
posthandover years. Unlike the rest of the Asian Tigers, Hong Kong’s colonial gov-
ernment lacked the incentives to invest in new infrastructure in science and technol-
ogy, whereas the SAR government largely failed in its premillennium biotech
institution building. Based on newly collected data, however, I argue that this stereo-
typical image is beginning to change. In the beginning of this article, I cited the 2012
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Science article as a first glimpse of what I consider to be a changing picture of Hong
Kong’s biotech sector. With the inauguration of the city’s new Innovation and Tech-
nologyBureau inNovember 2015 (Chan 2015), this picture is slowly developing into a
more elaborate painting. I am hopeful that the evolving biotech landscape in Hong
Kong will attract more dynamic studies from STS scholars in the near future.
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